Evaluation of methylphenidate effect on brain growth factor.
Phase 2
- Conditions
- ADHD.Disturbance of activity and attention
- Registration Number
- IRCT201108067237N1
- Lead Sponsor
- Guilan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
age below 18; absence of any other axis I diagnosis; absence of any neurological disorder; use of psychothropic drug within the last month; IQ>70.
Exclusion criteria: drug discontinue due to side effects(tics, hallucinations, depressed mood, OCD, ...); augmentation of any other psychotropic medication; occuring of any major neurological and psychiatric disorder (eg, depression, bipolare, psychotic disorders); acute and febral disease within current 2weeks.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method BDNF(Brain-derived neurotrophic factor) plasma level. Timepoint: Before treatment, 10 weeks after treatment. Method of measurement: ELISA.
- Secondary Outcome Measures
Name Time Method